Tectonic Therapeutic, Inc. (TECX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Tectonic Therapeutic reported revenue of $0. Net income was -$74.2M, or -$4.05 per diluted share. Operating activities generated -$60.1M of cash, leaving -$60.3M of free cash flow. At fiscal year end, Tectonic Therapeutic held $261.0M in total assets against $9.7M in total liabilities, including $253.8M of cash and equivalents.
Open the full interactive Tectonic Therapeutic financials → Quarterly statements, key ratios, valuation history and price charts.
Tectonic Therapeutic Key Stats
| Share Price | $21.31 |
|---|---|
| Market Cap | $404.1M |
| 52-Week Range | $16.09 – $37.93 |
| Shares Outstanding | 19.0 million (basic, 2026 Q2) |
Tectonic Therapeutic Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Goods Sold | — | — | $3.0M | $2.1M | $3.6M | $3.7M |
| Gross Profit | — | — | -$3.0M | -$2.1M | -$3.6M | -$3.7M |
| Operating Income | -$120.2M | -$118.8M | -$105.4M | $10.2M | -$58.0M | -$84.0M |
| Pre-Tax Income | -$119.7M | -$119.1M | -$105.9M | $12.5M | -$58.0M | -$72.9M |
| Income Tax | — | — | — | $377,000 | $0 | $1.2M |
| Net Income | -$119.7M | -$119.1M | -$105.9M | $12.2M | -$58.0M | -$74.2M |
| Diluted EPS | -$39.72 | -$33.36 | -$29.04 | $3.24 | -$6.83 | -$4.05 |
Tectonic Therapeutic Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$19.0M | -$19.2M | -$25.2M | -$22.3M |
| Diluted EPS | -$1.02 | -$1.05 | -$1.34 | -$1.18 |
Tectonic Therapeutic Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $259.7M | $189.6M | $92.6M | $98.0M | $141.2M | $253.8M |
| Current Assets | $267.2M | $199.1M | $100.0M | $100.3M | $146.9M | $257.4M |
| Total Assets | $271.2M | $203.8M | $103.9M | $101.1M | $152.9M | $261.0M |
| Current Liabilities | $16.6M | $19.4M | $13.1M | $6.4M | $11.6M | $9.7M |
| Total Long-Term Debt | — | $15.0M | $15.0M | — | — | — |
| Total Liabilities | $16.9M | $34.4M | $28.6M | $6.4M | $12.1M | $9.7M |
| Shareholders' Equity | $254.3M | $169.5M | $75.4M | $94.7M | $140.8M | $251.3M |
Tectonic Therapeutic Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$98.8M | -$98.0M | -$97.2M | -$63.2M | -$59.1M | -$60.1M |
| Cash From Investing | -$1.2M | -$2.5M | -$267,000 | $85.1M | -$156,000 | -$138,000 |
| Cash From Financing | $172.6M | $30.4M | $262,000 | -$16.0M | $171.7M | $173.4M |
| Free Cash Flow | -$100.0M | -$100.5M | -$97.5M | -$63.2M | -$59.2M | -$60.3M |
Figures from Tectonic Therapeutic's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Tectonic Therapeutic financials page for every line item.
Tectonic Therapeutic Company Profile
| Ticker | TECX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Watertown, Massachusetts |
| Incorporated in | New York |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001681087 |
Frequently Asked Questions
What was Tectonic Therapeutic's revenue in fiscal 2025?
Tectonic Therapeutic (TECX) reported revenue of $0 for fiscal 2025.
What is Tectonic Therapeutic's annual revenue history?
Tectonic Therapeutic's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Tectonic Therapeutic's net income in fiscal 2025?
Tectonic Therapeutic reported net income of -$74.2M for fiscal 2025.
What was Tectonic Therapeutic's earnings per share (EPS) in fiscal 2025?
Tectonic Therapeutic's diluted EPS was -$4.05 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Tectonic Therapeutic generate in fiscal 2025?
Tectonic Therapeutic generated -$60.3M of free cash flow in fiscal 2025.
What was Tectonic Therapeutic's revenue last quarter?
In its most recent reported quarter (2026 Q2), Tectonic Therapeutic reported revenue of $0.
How many shares of Tectonic Therapeutic are outstanding?
Tectonic Therapeutic reported a weighted average of 19.0 million basic shares outstanding in 2026 Q2.
What is Tectonic Therapeutic's market cap?
Based on its latest closing price, Tectonic Therapeutic (TECX) has a market capitalization of about $404.1M.
When does Tectonic Therapeutic's fiscal year end?
Tectonic Therapeutic's fiscal year end, as registered with the SEC, is December 31.
Where is Tectonic Therapeutic headquartered?
Tectonic Therapeutic lists its business address in Watertown, Massachusetts in its SEC filings.
Tectonic Therapeutic Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →